Apart from ERBB2 amplification and KRAS mutation in each of the two fetal adenocarcinoma (FET) patients in the cohort, no other gene alterations in any oncogenic driver and TP53 were detected (Fig 2b,c). This evidence concerns the gene TP53 and adenocarcinoma.